Arabic version: قطاع التكنولوجيا الطبية يعارض إصلاحات الضرائب للحكومة العمالية

Australia’s medical technology sector has expressed strong concerns regarding the recent changes to capital gains tax (CGT) and research and development (R&D) tax incentives proposed by the Labor government. Industry groups argue that these reforms threaten the viability of local startups and their ability to bring innovative products to market.

According to ABC News, nine peak health and medical technology industry bodies have signed a joint letter sent to Treasurer Jim Chalmers this week asking the federal government to adjust some of the changes in last month’s budget. They warn that the new ten-year limit on refundable R&D tax offsets will disproportionately impact health startups, which often require more than a decade to achieve profitability.

The reforms include a shift from a flat 50 percent CGT discount to a model tied to inflation, further complicating the financial landscape for emerging companies. The letter from industry groups highlights that the time-consuming process of developing medical technologies—often averaging 17 years—makes the proposed tax reforms a significant hurdle for domestic firms.

The Labor government is moving forward with its tax overhaul, having passed the omnibus bill through the House of Representatives. Despite the potential for a longer inquiry into the changes, senior Labor figures remain optimistic about passing the bill in the Senate during the upcoming parliamentary session.

Industry leaders have voiced their frustration, stating that the limitations on R&D incentives and the CGT changes may force many companies to reconsider their operations in Australia. They emphasize the need for policy adjustments to ensure the continued success of the medical technology sector, which supports over 350,000 jobs across almost 3,000 organizations in the country.